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ABSTRACT
Between January 1990 and December 1997, 182 adults with acute lymphoblastic leukemia (ALL) received
allogeneic hematopoietic cell transplants according to Fred Hutchinson Cancer Research Center protocols.
Patients eligible for transplantation included those in first remission, especially those at high risk of relapse
(n  41), and any patient in second or later remissions (n  46) or in relapse (n  95). The median patient age
was 29.4 years (range, 18.0-57.6 years), and the median duration of disease was 13.3 months (range, 2.4-221.9
months). Fifty-six patients had Philadelphia chromosome–positive ALL. Most patients (n  169) received a
conditioning regimen of cyclophosphamide 120 mg/kg plus 12.0 to 15.75 Gy of total body irradiation and a
combination of cyclosporine and methotrexate as graft-versus-host disease (GVHD) prophylaxis. One hundred
twenty-one patients received stem cells from HLA-identical donors (88 related donors and 33 unrelated
donors), and 61 received stem cells from HLA-mismatched donors (26 related donors and 35 unrelated
donors). Actuarial disease-free survival at 5 years was 21% for all patients, 43% for patients in first remission,
24% for patients in second or later remissions, and 9% for patients in relapse. Univariate and multivariate Cox
regression analyses were performed to identify factors associated with survival, relapse, nonrelapse mortality,
and disease-free survival. Factors significantly associated (P < .01) with improved survival and disease-free
survival included younger age and being in first remission. Lower disease-free survival was associated with
receiving cyclosporine alone as GVHD prophylaxis (P< .01). Risk of relapse correlated only with disease status
at transplantation: patients who underwent transplantation in relapse had a 9-fold increased risk compared with
patients who underwent transplantation in first remission. Acute or chronic GVHD had no significant effect on
relapse. Increased nonrelapse mortality was associated with HLA-mismatched donors, a positive cytomegalo-
virus serology before transplantation, and GVHD prophylaxis with only cyclosporine. Patients with Philadel-
phia chromosome–positive ALL had survival and relapse rates similar to patients with normal cytogenetics.
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INTRODUCTION
The development of intensive chemotherapeutic
regimens for adults with acute lymphoblastic leukemia
(ALL) has resulted in ﬁrst remission rates of 80%
and 5-year long-term disease-free survivals of 35% to
40% [1-3]. Prognostic factors associated with a low
probability of cure with conventional therapy include
a high white blood count (WBC) at diagnosis, speciﬁc
clonal cytogenetic abnormalities (eg, the presence of a
Philadelphia [Ph] chromosome), older age, B-cell
immunophenotype, and extramedullary disease [2,4-
9]. Patients at high risk of relapse are often considered
candidates for hematopoietic cell transplantation
(HCT) in ﬁrst remission. Patients at lower risk of
relapse are, in general, not referred for transplantation
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until they have relapsed. Other factors considered
important in recommending myeloablative HCT vary
among transplant centers; however, patient age, co-
morbid medical conditions, response to conventional
therapy, and availability of donor hematopoietic cells
all play an important role. To further deﬁne those
factors associated with acceptable nonrelapse mortal-
ity (NRM) and long-term disease-free survival (DFS),
we performed a retrospective analysis of our adult
ALL patients who received an allogeneic HCT be-
tween 1990 and 1997.
MATERIALS AND METHODS
Patients
One hundred eighty-two consecutive adults (18
years old) with ALL who received an allogeneic HCT
in Seattle, WA, between January 1, 1990, and Decem-
ber 31, 1997, are included in this retrospective anal-
ysis. The transplantations were performed at the Fred
Hutchinson Cancer Research Center (n  166) or the
Veterans Affairs Puget Sound Healthcare System (n
16). Protocols and consent forms were approved by
the Institutional Review Board of the Fred Hutchin-
son Cancer Research Center, and written, informed
consent was obtained from all patients and donors.
Transplantation in ﬁrst remission was offered to
any adult ALL patient who had a suitably matched
donor and who chose to undergo transplantation early
in the disease course. Most patients who underwent
transplantation in ﬁrst remission had at least 1 factor,
other than age and B-cell phenotype, that was consid-
ered to be associated with a high risk for relapse with
conventional therapy, including (1) Ph or other un-
favorable clonal cytogenetic abnormality, (2) history
of extramedullary disease, or (3) a WBC at diagnosis
30  109/L.
Pretransplant patient characteristics are summa-
rized in Table 1. Patients were classiﬁed as having B-
or T-cell ALL on the basis of either immunopheno-
typing reports or assessments provided in clinical
summaries. B-cell maturity at diagnosis was character-
ized as immature or mature. Immature B cells ex-
pressed terminal deoxynucleotidyl transferase, CD34,
CD10, or a combination of these; mature B cells
expressed CD20, CD22, or surface immunoglobulin
and did not express any immature markers [10]. Too
few patients had complete phenotyping data available
to analyze the outcome of transplantation on the basis
of speciﬁc phenotypic markers. Cytogenetic studies
were performed on bone marrow or peripheral blood
cells. The karyotypes were grouped as normal, Ph,
or positive for other clonal abnormalities. Patients
were considered to be Ph if the Philadelphia chro-
mosome was detected either at diagnosis or at the time
of relapse. Reverse transcriptase-polymerase chain re-
action and ﬂuorescence in situ hybridization methods
to detect the BCR/ABL gene rearrangement were not
routinely performed.
Donor Selection and Stem Cell Collection
Donor characteristics are summarized in Table 1.
The median donor age, which was available for 152
donors, was 34.2 years (range, 2.6-67.0 years). HLA
compatibility was determined by serologic typing for
class I antigens and by either serological or molecular
typing for class II antigens, depending on the technol-
ogy available at the time of the transplantation.
Eighty-eight patients received transplants from HLA-
identical related donors; 26 received transplants from
HLA-mismatched related donors; 33 received trans-
plants from HLA-matched unrelated donors; and 35
received transplants from HLA-mismatched unrelated
donors. The stem cell source was bone marrow only in
159 patients, peripheral blood stem cells (PBSC) in 19
patients, bone marrow plus PBSC in 2 patients, and
umbilical cord blood in 2 patients.
Transplantation Regimens
Table 2 summarizes the preparative regimens,
stem cell doses, and posttransplantation immunosup-
pression given. Total body irradiation (TBI) was de-
livered by dual opposing cobalt sources for all regi-
mens except the 14.4-Gy regimen, which was
delivered by a linear accelerator. Most patients (n 
126) received cyclophosphamide 60 mg/kg daily for 2
days plus 13.2 to 13.5 Gy of fractionated TBI. Eighty-
eight percent of patients received a cyclosporine
(CSP)-based graft-versus-host disease (GVHD) pro-
phylaxis regimen; CSP plus methotrexate was the
most common regimen and was administered to 105
(58%) patients [11].
Engraftment
Myeloid engraftment was deﬁned as the ﬁrst of 7
consecutive days on which the absolute neutrophil
count was 0.5  109/L. Platelet engraftment was
deﬁned as the ﬁrst day of a sustained, untransfused
platelet count 20  109/L. Engraftment data were
available for the ﬁrst 100 days after transplantation.
Acute and Chronic GVHD
Acute GVHD was diagnosed and graded accord-
ing to previously published criteria [12,13]. All pa-
tients who engrafted were considered evaluable for
acute GVHD. Chronic GVHD was assessed for those
patients who survived at least 80 days after transplan-
tation [14].
Statistical Analyses
Survival and leukemia-free survival probabilities
were estimated by the Kaplan-Meier method [15].
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NRM and relapse were determined with cumulative
incidence estimates, treating relapse and death, re-
spectively, as competing risk events [16]. All time-to-
event end points were censored at the time of last
contact. Risk factors for all time-to-event end points
were evaluated in univariate and multivariate models
by using the Cox proportional hazards regression
models [17].
In models for relapse, GVHD was evaluated as a
time-dependent covariate to assess a possible graft-
versus-leukemia (GVL) effect. Separate univariate
analyses were performed for (1) all patients, (2) pa-
Table 1. Characteristics of 182 Adult ALL Patients and Their Stem Cell Donors
Characteristic n (range) %
Median patient age (y) 29.4 (18.0 - 57.6)
<40 143 79
>40 39 21
Donor/recipient sex
M/M 66 36
M/F 33 18
F/M 49 27
F/F 34 19
FAB classification
L1 44 24
L1, L2 8 4
L2 50 27
L3 4 2
Unknown 76 42
Immunophenotype
B cell, immature 119 65
B cell, mature 11 6
B cell, maturity unknown 10 5
T cell 33 18
Unknown 9 5
Cytogenetics
Normal 40 22
Ph* 56 31
Other clonal abnormality† 45 26
Unknown 41 21
Median WBC  109/L at diagnosis 15.8 (1.1-500)
Extramedullary disease‡
CNS only 13
CNS and other sites 2
Testis 3
Nodal 2
Other 4
Median disease duration (mo) 13.3 (2.4-221.9)
Disease status at transplantation
First remission 41 23
Second or later remissions 46 25
Relapse 95 52
Median donor age (y)§ 34.2 (2.6-67.0)
Donor/recipient HLA compatibility
Related/matched 88 48
Related/mismatched 26 14
Unrelated/matched 33 18
Unrelated/mismatched 35 19
Donor/recipient CMV serology
/ 65 36
/ 39 22
/ 36 20
/ 40 22
CNS indicates central nervous system.
*Ph includes patients with a t(9;22) only or t(9;22) plus additional clonal abnormalities.
†Includes unfavorable risk groups: t(8;14), n  1; t(1;19), n  3; monosomy 7, n  7. There were no patients with t(4;11). Four patients
had trisomy 8, but all were Ph.
‡Extramedullary disease occurring before or at the time of transplantation.
§Data were available for 152 donors.
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tients who underwent transplantation in remission,
and (3) patients who underwent transplantation in
relapse. The severity of acute GVHD (grades 0-I
versus grades II-IV and grades 0-II versus grades III-
IV), the presence or absence of chronic extensive
GVHD, and the presence of either grades II through
IV acute GVHD or clinical extensive GVHD were
evaluated for their effects on relapse within the 3
groups of patients.
Step-up and step-down regression methods were
used to identify factors for inclusion in the multivar-
iate regression models. Factors were included either
on the basis of statistical signiﬁcance or if their inclu-
sion modiﬁed the effect of another factor in the model
by more than 10%. No adjustments were made for
multiple comparisons. Because of the number of com-
parisons made, P values .01 were viewed as signiﬁ-
cant, and P values between .01 and .05 were viewed as
suggestive.
RESULTS
Engraftment
Engraftment data were available for 145 of the 182
patients. One hundred thirty-eight of the 145 patients
survived 21 days, and their median time to myeloid
engraftment was 19 days (range, 9-57 days) after
transplantation. Seven patients who died 21 days
after transplantation also achieved absolute neutrophil
counts 0.5  109/L. Of the patients who achieved
myeloid engraftment, platelet engraftment data were
available for 100 patients. These 100 patients achieved
self-sustained platelet counts of 20  109/L at a
Table 2. Transplantation Regimens and Outcome Data of 182 Adult Patients with ALL
Variable n (range) %
Preparative regimen*
CY, 12.0 Gy TBI 10 5
CY, 13.2-13.5 Gy TBI 126 69
CY, 14.4-15.75 Gy TBI 33 18
Various chemotherapy  13.2-15.75 Gy TBI 5 3
Chemotherapy only 8 4
Median stem cell dose†
BM  108 TNC/kg (n  158) 2.42 (0.36-20.3)
PBSC  106 CD34 cells/kg (n  19) 11.3 (0.05-27.4)
Cord blood  107 TNC/kg (n  1) 1.32
GVHD prophylaxis‡
CSP  MTX 105 58
CSP  steroids / other 30 16
CSP only 26 14
Other 19 10
None 2 1
Acute GVHD 175
Grades 0-I 48 27
Grades II-IV 127 73
Median day of onset acute GVHD 15 (4-76)
Chronic extensive GVHD (N  124) 53 43
Relapse 63
Median day of relapse 141 (9-644)
Survival
Patients alive 38 21
Patients dead 144 79
Causes of death
Relapse 61 43
Infection 38 26
Organ failure 17 12
Acute GVHD 5 3
Chronic GVHD 3 2
Hemorrhage 3 2
Interstitial pneumonia 2 1
Graft failure 2 1
Other 2 1
Unknown 11 8
*CY indicates 120 mg/kg of cyclophosphamide, TBI  total body irradiation
†TNC indicates total nucleated cells. No cell doses were available for 1 patient who received bone marrow (BM) and one who received cord
blood. Two additional patients received both BM and PBSC.
‡GVHD indicates graft-versus-host disease; CSP, cyclosporine; MTX, methotrexate.
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median time of 19 days (range, 4-70 days) after trans-
plantation. Of the 38 patients who remained platelet
transfusion dependent, 22 died between days 22 and
100, 12 died after day 100 (9 after returning home),
and 4 are long-term survivors but returned home
while still platelet transfusion dependent.
Regimen-Related Toxicity
The cumulative incidence of NRM before day 100
for all 182 patients was 34%. NRM was not signiﬁ-
cantly different for patients who underwent transplan-
tation in remission compared with those who under-
went transplantation in relapse (Figure 1).
Acute and Chronic GVHD
One hundred twenty-seven (73%) of 175 patients
for whom adequate data were available developed
grades II through IV acute GVHD. The median time
of onset of acute GVHD was day 15 (range, 4-76
days). Of the 124 patients who survived at least 80
days, 53 (43%) developed chronic extensive GVHD.
Relapse
Sixty-three patients relapsed at a median time of
141 days after transplantation. Eleven patients re-
lapsed more than 1 year after transplantation; the
latest relapse occurred 1.8 years after transplantation.
The cumulative incidence of relapse at 5 years for all
patients was 35%. The probability of relapse was sig-
niﬁcantly associated with the stage of disease at trans-
plantation (Figure 2). Patients in ﬁrst remission at the
time of transplantation had the lowest probability of
relapse (15% at 2 years). The latest of the 6 relapses
among these 41 patients occurred 1 year after trans-
plantation. There was no signiﬁcant GVL effect
within any patient group in univariate analyses: the
strongest association (P  .05) was seen in patients
who underwent transplantation in relapse who devel-
oped either grades II to IV acute GVHD or chronic
extensive GVHD. When this subgroup of patients in
relapse was evaluated in the multivariate analysis,
however, the effect of acute GVHD on relapse did not
achieve statistical signiﬁcance (P  .28). Similarly, if
more severe—ie, grade III or IV—acute GVHD was
compared with less severe—grades 0 to II—acute
GVHD, a signiﬁcant GVL effect could not be shown.
Survival and Causes of Death
Thirty-eight patients are alive; 144 have died.
Twenty-seven of the 144 patients died early,21 days
after transplantation. Actuarial survival at 5 years was
21% for all 182 patients. Survival and DFS were
signiﬁcantly associated with stage of disease at trans-
plantation; patients who underwent transplantation in
ﬁrst remission had a 5-year DFS of 43% (Figure 3).
Survival for patients with Ph ALL was comparable to
that of patients with normal cytogenetics (26% versus
Figure 2. Cumulative incidence of relapse for 182 adult patients
with ALL according to stage of disease at transplantation. The
probability of relapse at 5 years after transplantation was 15% for
patients in ﬁrst remission, 30% for patients in second or later
remissions, and 45% for patients in relapse. C.I. indicates cumula-
tive incidence.
Figure 3. Disease-free survival (DFS) for 182 adult patients with
ALL according to stage of disease at transplantation. DFS at 5 years
after transplantation was 43% for patients in ﬁrst remission, 23%
for patients in second or later remissions, and 9% for patients in
relapse.
Figure 1. Cumulative incidence of nonrelapse mortality (NRM) for
182 adult patients with ALL according to stage of disease at trans-
plantation. The cumulative incidence of NRM at 5 years was 42%
for patients in ﬁrst remission, 46% for patients in second or later
remissions, and 45% for patients in relapse. C.I. indicates cumula-
tive incidence.
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24% at 5 years, respectively; Figure 4). The most
frequent cause of death was recurrent disease (n 61).
Infection was the second leading cause of death and
occurred in 38 patients. Twenty-ﬁve of the 27 early
deaths (21 days) were related to infection (n 16) or
organ failure (n  9). Other causes of death are sum-
marized in Table 2.
Prognostic Factors
Univariate Analyses. Table 3 lists those factors
evaluated in the univariate analyses; death, DFS, re-
lapse, and NRM were end points. Disease status at
transplantation was signiﬁcantly associated with sur-
vival, DFS, and probability of relapse, but not with
NRM. Donor type was important for all end points
except relapse, with HLA matching being most im-
portant whether or not the donors were related to the
recipients. No donor or patient sex combination was
signiﬁcantly associated with any end point; however,
there was a suggestion that female/female pairs had a
greater risk of death (P  .04) and decreased relapse-
free survival (P  .05). Patients with B-cell ALL had
a marginally higher risk of death (P  .07) and NRM
(P  .06) compared with patients with T-cell disease.
Patients who received GVHD prophylaxis with CSP
alone had a higher risk of death (P  .03) and de-
creased DFS (P  .04) compared with patients who
received methotrexate and CSP. Age, marrow cell
dose, year of transplantation, Ph cytogenetics, WBC
at diagnosis, and the presence of extramedullary dis-
ease at transplantation did not correlate with any end
point examined in univariate models. The potential
effect of other favorable or unfavorable clonal cytoge-
netic abnormalities on survival and relapse was also
examined (data not shown) [5,18]. Transplantation
outcomes in these subgroups were not different from
those of patients with a normal karyotype. Patients
with a positive cytomegalovirus (CMV) serology had a
marginally increased risk of NRM compared with
CMV-negative patients (P  .04), whereas patients
whose donors were CMV positive had a marginally
increased risk of relapse compared with patients
whose donors were CMV negative (P  .05). A po-
tential GVL effect was suggested only in patients who
were in relapse at the time of transplantation and who
developed either grades II to IV acute or clinical
extensive chronic GVHD (P  .05).
The risk of dying early (21 days after transplan-
tation) was also assessed in a univariate Cox regression
model. The only factors that were suggestive of being
associated with early death were being in relapse (P 
Figure 4. Actuarial survival for 143 adult patients with ALL based
on cytogenetic markers of disease. Survival at 5 years was 24% for
patients with normal cytogenetics, 26% for Ph patients, and 15%
for patients with abnormal cytogenetics but who were Ph.
Table 3. Factors Included in Univariate Analyses
Factor Option
Patient age <40 vs. >40 y
Remission/relapse status at transplantation First remission vs second or later remission vs. relapse
Patient sex Female (F) vs. male (M)
Donor type Related donor (matched vs. mismatched) vs. unrelated donor
(matched vs. mismatched)
Donor/patient sex M/M vs. F/F vs. F/M vs. M/F
Donor/patient HLA matching Matched vs. mismatched
Immunophenotype Immature B cell vs. mature B cell vs. T cell
Immature B cell vs. mature B cell
Cytogenetics Normal vs. Ph vs. other abnormality vs. unknown
GVHD prophylaxis CSP vs. CSP  MTX vs. CSP  steroids  others vs. other/none
WBC at diagnosis <30  109/L vs. >30  109/L
Extramedullary disease at transplantation Yes vs. no
Patient CMV serology before transplantation Negative vs. positive
Donor CMV serology before transplantation Negative vs. positive
Marrow cell dose <2.4 X 108/kg vs. >2.4 X 108/kg
Year of transplantation 1
Acute GVHD* Grades 0-1 vs. grades II-IV; grades 0-II vs. grades III-IV
Clinical extensive chronic GVHD* Yes vs. no
Acute GVHD, grades II-IV, or clinical extensive chronic GVHD* Yes vs. no
MTX indicates methotrexate.
*Examined as time-dependent covariate for effect on relapse only.
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.11); having a mismatched, related donor (P  .01);
and female/female donor/recipient pairs (P  .04).
Multivariate Analyses. Results of the multivariate
Cox regression analyses are summarized in Table 4.
Patients younger than 30 years of age and patients
who underwent transplantation in ﬁrst remission had
signiﬁcantly improved survival and DFS (P  .01).
Receiving only CSP for GVHD prophylaxis led to
decreased DFS (P  0.01). Patients with HLA-mis-
matched donors, B-cell phenotype, WBC at diagnosis
30  109/L, and female/female donor/recipient
pairs seemed to have an increased risk of death, but P
values were .04 and .06. Higher transplant-related
mortality was signiﬁcantly associated with HLA-mis-
matched donor/recipient pairs, receiving only CSP as
GVHD prophylaxis, and CMV-positive status before
transplantation. Patients with T-cell ALL had mar-
ginally lower transplant-related mortality compared
with patients with B-cell ALL (P  .03). Relapse was
most strongly associated with being in relapse at the
time of transplantation (P  0.01) and with female/
female donor/recipient pairs as compared with male/
male donor/recipient pairs (P  .01).
DISCUSSION
In this study, the 2 factors most signiﬁcantly asso-
ciated with an improved outcome for adults with ALL
after allogeneic HCT were younger patient age and
being in remission, especially ﬁrst remission, at the
time of transplantation. The lower survival noted in
patients who underwent transplantation in relapse was
primarily due to a higher rate of relapse after trans-
plantation. Receiving CSP alone for GVHD prophy-
laxis had a signiﬁcant adverse effect on both NRM and
DFS. Increased NRM was also seen in patients who
had HLA-mismatched donors and those who were
CMV positive before transplantation. Survival of pa-
tients with Ph ALL was similar to that for patients
with normal cytogenetics.
In 1987, we published the results of our ﬁrst 46
pediatric and adult patients with ALL in ﬁrst remis-
sion who received HLA-identical sibling donor bone
marrow transplants [19]. DFS at 5 years was 28%. In
1991, in an update of our results of HLA-identical
sibling transplants in 192 adult patients with ALL, the
5-year DFS for the 41 patients who underwent trans-
plantation in ﬁrst remission was 21% [20]. These
results have improved over time, with the current
group of 41 adult patients with ALL in ﬁrst complete
remission transplanted from either related or unre-
lated donors having a 5-year DFS of 43%. A similar
improvement in DFS was seen in patients who under-
went transplantation in second or later remissions
(15% to 33%). This increase in DFS is primarily
associated with a decrease in NRM. With use of cu-
mulative incidence methodology to calculate both
NRM and the incidence of relapse by using the orig-
inal data from the 1991 study, the 5-year cumulative
incidence of relapse for patients who underwent trans-
plantation in ﬁrst remission was 29%. The incidence
of NRM was 49%. The corresponding values for
relapse and NRM in this study were 21% and 33%.
For patients who underwent transplantation in second
or later remissions, NRM in the 2 studies decreased
from 55% to 33%, whereas the incidence of relapse
was unchanged (30% versus 33%). Beginning in 1992,
multiple changes in supportive care were instituted,
including CMV prophylaxis, fungal prophylaxis, and
consistent use of combination regimens, especially
methotrexate and CSP, for GVHD prophylaxis. Such
measures likely contribute to the decreased NRM in
this analysis of patients who underwent transplanta-
tion in remission.
Over time, no signiﬁcant differences in DFS,
NRM, or the cumulative incidence of relapse were
found among patients who underwent transplantation
in relapse in our studies. Any increase in DFS associ-
ated with improved supportive care is masked by the
high probability of relapse after transplantation (45%
in this study). Improving the outcome in this group of
patients will depend, in part, on the development of
more sensitive methods to detect minimal residual
disease to treat these patients earlier. New approaches
to prevent and treat relapse after transplantation are
also needed.
In an effort to improve DFS by decreasing relapse
rates after transplantation, many studies are currently
focusing on modulating GVHD to produce a GVL
effect. Several analyses support the importance of a
GVL effect in ALL [21]. In a large cohort of pediatric
and adult patients with ALL in ﬁrst complete remis-
sion analyzed by the International Bone Marrow
Transplant Registry (IBMTR), the presence of acute
GVHD, grades I to IV, was signiﬁcantly associated
with a lower probability of relapse (P  .004) [22]. A
more recent IBMTR analysis compared outcomes of
HLA-identical sibling transplants for patients with
ALL in ﬁrst or second remission on the basis of cell
lineage (T versus B cell) [23]. Patients who developed
either grades II to IV acute GVHD or chronic
GVHD had a signiﬁcantly decreased risk of relapse
compared with those who had no or grade I acute
GVHD. Chronic extensive GVHD was also associ-
ated with a lower probability of relapse [23].
In our 1991 summary of allogeneic transplants for
adult ALL, we also reported a strong association of
grade II to IV acute GVHD with decreased relapse
rates [20]. With cumulative incidence methodology,
the probability of relapse at 5 years for those patients
with grades 0 or I GVHD was 54%, compared with
23% for patients with grades II to IV GVHD (P 
.001). In our current study, however, a strong GVL
K. Doney et al.
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Table 4. Multivariate Cox Regression Analyses of Factors Associated with Death, Transplant-Related Mortality, Relapse, and Disease-Free Survival
Covariate Death Transplant-Related Mortality Relapse Disease-Free Survival
Relative Risk P Value 95% CI Relative Risk P Value 95% CI Relative Risk P Value 95% CI Relative Risk P Value 95% CI
Age at transplantation (y)
<40 1.0 — — 1.0 — —
>40 1.86 .01 (1.16-2.97) 1.91 <.01 (1.23-2.96)
Status at transplantation
First remission 1.0 — — 1.0 — — 1.0 — —
Second or later remissions 1.78 .09 (0.90-3.42) 2.31 .17 (0.69-7.69) 1.57 .14 (0.86-2.84)
Relapse 3.06 <.01 (1.70-5.37) 9.32 <0.01 (3.19-27.18) 3.46 <.01 (2.05-5.75)
Donor/patient sex
Male/male 1.0 — — 1.0 — —
Female/female 1.77 .04 (1.03-3.03) 3.74 <.01 (1.42-9.86)
Male/female 1.01 .98 (0.55-1.84) 1.53 .42 (0.55-4.28)
Female/male 1.25 .42 (0.73-2.12) 0.95 .92 (0.34-2.64)
Donor/Recipient HLA
Matched 1.0 — — 1.0 — — 1.0 — — 1.0 — —
Mismatched 1.52 .06 (0.99-2.34) 2.07 <.01 (1.21-3.54) 0.39 .06 (0.14-1.05) 1.48 .05 (1.00-2.17)
WBC at diagnosis (n  153)
<30  109/L 1.0 — — 1.0 — — 1.0 — —
>30  109/L 1.57 .04 (1.02-2.40) 1.07 .76 (0.64-1.86) 2.61 .02 (1.15-5.93)
Immunophenotype (n  173)
B cell 1.0 — — 1.0 — — 1.0 — —
T cell 0.56 .04 (0.32-0.98) 0.40 .03 (0.18-0.89) 0.66 .09 (0.36-1.08)
B-cell type (n  154)
Immature 1.0 — —
Mature 2.40 .08 (0.89-6.50)
Cytogenetics
Normal 1.0 — — 1.0 — — 1.0 — —
Ph 0.62 .11 (0.34-1.12) 0.95 .92 (0.32-2.78) 0.63 .09 (0.36-1.08)
Other 1.53 .14 (0.87-2.69) 2.27 .13 (0.79-6.52) 1.25 .39 (0.75-2.09)
Unknown 1.57 .16 (0.84-2.93) 2.46 .11 (0.81-7.51) 1.41 .21 (0.83-2.40)
Patient CMV serology
Negative 1.0 — — 1.0 — —
Positive 1.99 .01 (1.18-3.36) 1.41 .06 (0.98-2.04)
Donor CMV serology
Negative 1.0 — —
Positive 1.49 .04 (1.03-2.16)
Marrow cell dose
<2.4  108/kg 1.0 — —
>2.4  108/kg 1.48 .31 (0.69-3.17)
GVHD prophylaxis
CSP  MTX 1.0 — — 1.0 — — 1.0 — —
CSP only 1.65 .09 (0.93-2.90) 2.53 <.01 (1.28-5.01) 1.96 <.01 (1.19-3.22)
CSP  MTX  other 0.91 .75 (0.52-1.60) 1.11 .77 (0.54-2.31) 0.92 .77 (0.55-1.56)
Other/none 1.19 .60 (0.62-2.26) 0.74 .54 (0.29-1.92) 1.69 .06 (0.97-2.95)
Acute grade II-IV or clinical extensive GVHD*
No 1.0 — —
Yes 0.57 .28 (0.21-1.57)
CI indicates conﬁdence interval; MTX, metrotrexate.
*Examined only for relapse. Included as a time-dependent covariate.
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effect of either acute or chronic extensive GVHD
could not be shown. Reasons for lack of a GVL effect
in the current analysis are unclear.
None of the factors commonly associated with a
poor prognosis with conventional therapy for ALL
were found to affect the outcome of transplantation in
this analysis. The probabilities of survival and relapse
for the 56 patients with Ph ALL were not different
from those of patients with normal cytogenetics. The
2- and 5-year probabilities of survival for our 56 pa-
tients with Ph ALL were 30% and 26%, respec-
tively. These results are similar to those reported by
the IBMTR for 67 patients with PhALL who re-
ceived HLA-identical sibling donor transplants be-
tween 1978 and 1990: leukemia-free survival at 2 years
was 31% [24]. Reports in 2 small studies have reported
a 3-year DFS of 21.8% (11 patients) and an actual
survival of 60% (10 patients) [25,26]. To date, the best
results for patients with Ph ALL in ﬁrst remission
from HLA-identical sibling donors has been reported
by Snyder et al. [27]. In a group of 23 patients, the
3-year DFS was 65%. For those patients who under-
went transplantation after 1992, the 3-year DFS was
81% and the probability of relapse was only 12%. Use
of an etoposide/TBI conditioning regimen was
thought to play an important role in improving out-
come in this group of patients.
Donor/recipient HLA compatibility remains an
important criterion for choosing donors, especially
unrelated donors. HLA-mismatched donor/recipient
pairs have poorer survival and increased transplant-
related mortality compared with HLA-matched do-
nors and recipients [28]. In this series, the outcome of
HLA-identical unrelated donor transplant recipients
was similar to that for HLA-related donor transplant
recipients. With the reﬁnement of HLA typing by
using molecular methods, the results with unrelated
donor transplants should continue to improve [29].
Ongoing reﬁnements of HCT to decrease NRM
include the use of PBSC as the stem cell source,
infusion of higher stem cell doses, and targeting ra-
diotherapy by using radiolabeled monoclonal antibod-
ies directed at leukemic cells [30-32]. Targeted mono-
clonal antibody therapy may also help to decrease
relapse rates. Regimen-related toxicity can now be
largely avoided in older and younger patients with
end-organ dysfunction related to prior chemoradia-
tion therapy by using nonmyeloablative conditioning
regimens [33,34]. In the nonmyeloablative setting, the
ability to produce a lasting GVL effect will ultimately
be tested. Until an effective, reproducible means of
decreasing relapse rates is found, however, signiﬁcant
improvement in DFS in patients with ALL, especially
older patients who are not eligible for myeloablative
HCT, will remain elusive.
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